Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 14, 2019
Daily News
November 14, 2019
- Big 4 Japan Wholesalers Eke Out 1% Operating Margins: Jiho Tally
November 14, 2019
- PMD Law Amendment Bill Clears Lower House Health Panel
November 14, 2019
- Forteo, Enbrel Biosimilars OK’ed for Self-Injection; Evrenzo under Flat-Fee System
November 14, 2019
- Chuikyo Rep Calls for Modifying Re-Pricing Criteria with Eye to Xolair’s Pollen Allergy Use
November 14, 2019
- Panel OKs Orphan Status for 3 Cell, Gene Therapies
November 14, 2019
- Kyowa Pharma Set to Accelerate Beyond-the-Pill Growth after Lupin’s Divestment Deal: Chief
November 14, 2019
- Otsuka/Avanir to Carry On Development of Alzheimer’s Agitation Drug
November 14, 2019
- Otsuka’s Pharma Biz Zooms 14.0% in January-September on 4 Global Brands
November 14, 2019
- Ajinomoto, Kanagawa Cancer Center Team Up for Research for Next-Gen Treatment/Diagnosis Technology
November 14, 2019
- Rohto to Snap Up Nitten Pharmaceutical to Tap Into Ethical Eye Drop Arena
November 14, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…